Clinical Trial Information Request for Protocol 2025P000030
Title A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 52-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (EFC17600)
PI Site
Directions: Type your name, contact email and phone number (optional) into the boxes below then click Save to Submit your request for information about this study.
Name Email
Phone